CJC-1295 vs Ipamorelin: What the Research Actually Shows
Two peptides, two different mechanisms, one shared goal. Here's what the published evidence actually says about each.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone that extends GH pulse duration, while Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin to trigger GH release. They act on different receptors and have distinct evidence bases: CJC-1295 has small human pharmacokinetic trials, while Ipamorelin's human data is limited and most evidence comes from animal studies. Neither compound has received FDA approval, and research-grade versions sold online are not approved drugs.
What Are These Two Peptides?
CJC-1295 is a synthetic peptide derived from the first 29 amino acids of growth hormone-releasing hormone (GHRH), with modifications designed to extend its half-life. The original GHRH(1-29) analog breaks down quickly in plasma. CJC-1295 addresses that by incorporating amino acid substitutions that resist enzymatic cleavage. A further variant, CJC-1295 with DAC (Drug Affinity Complex), adds a lysine-maleimide linker that allows the peptide to bind covalently to albumin in the bloodstream, stretching its half-life from minutes to several days.
Ipamorelin is a pentapeptide, meaning it is built from just five amino acids. It belongs to the growth hormone secretagogue (GHS) class and was developed in the late 1990s as a selective, clean-signal GH releaser. Unlike earlier secretagogues such as GHRP-6, Ipamorelin was specifically engineered to avoid triggering significant cortisol or prolactin release alongside GH, which made it scientifically interesting as a research tool for isolating GH-related effects.
The two compounds are often discussed together because researchers and vendors frequently pair them, but they are structurally unrelated and work through entirely different receptor systems. Understanding that distinction is the starting point for reading the evidence honestly.
How Does Each Mechanism Differ?
CJC-1295 binds to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. Activation of this receptor stimulates the synthesis and release of growth hormone in a pattern that mirrors the body's natural pulsatile signaling, just with a longer-lasting stimulus. Because it works through the GHRH pathway, it tends to amplify the amplitude of existing GH pulses rather than creating entirely new ones.
Ipamorelin works through a separate receptor: the growth hormone secretagogue receptor type 1a (GHS-R1a), which is also the receptor activated by the endogenous hormone ghrelin. GHS-R1a agonism triggers GH release through a calcium-dependent pathway inside pituitary cells. The selectivity that defines Ipamorelin comes from its relatively weak binding to receptors responsible for ACTH and cortisol release, a property that distinguishes it from older GHRPs in preclinical comparisons.
When the two are combined in research settings, the rationale is that GHRH-pathway stimulation and GHS-R1a stimulation are synergistic at the pituitary level. A 1999 study in the Journal of Endocrinology by Raun et al. described Ipamorelin's selectivity profile in rats and pigs, noting that it produced GH release comparable to GHRP-6 with substantially less effect on cortisol. That selectivity finding is frequently cited but originates in animal data, not human trials.
What Does the Human Evidence Actually Look Like?
CJC-1295 has more human pharmacokinetic data than Ipamorelin. A 2006 study published in the Journal of Clinical Endocrinology and Metabolism by Ionescu and Frohman examined CJC-1295 with DAC in 65 healthy adults across multiple dose cohorts. Participants in the trial received single and multiple subcutaneous injections, and researchers measured GH and IGF-1 levels over time. The study found dose-dependent increases in mean GH concentration and IGF-1 levels that persisted for up to six days after a single injection, consistent with the albumin-binding mechanism. This is a genuine human pharmacokinetic trial, though it was not a long-term efficacy or safety study.
Ipamorelin's human evidence base is thinner. Most published work is in rodents and pigs. One area where human data exists is postoperative ileus: a clinical trial registered on ClinicalTrials.gov (NCT00397956) investigated an oral formulation of Ipamorelin for gastrointestinal motility after bowel surgery. That trial was conducted by Helsinn Therapeutics and reached Phase 2. Results were not published in a peer-reviewed journal in a form that supports broad efficacy conclusions, and the program did not advance to approval. Outside of that GI-motility program, published human data on Ipamorelin is sparse.
The evidence gap matters for anyone trying to compare these two compounds fairly. CJC-1295 has at least one peer-reviewed human pharmacokinetic study with a reasonable sample size. Ipamorelin's selectivity profile, which is its main selling point in vendor marketing, rests almost entirely on animal studies. Treating those two evidence bases as equivalent is a mistake.
Regulatory Status and Research Classification
Neither CJC-1295 nor Ipamorelin has received approval from the FDA for any indication. No branded pharmaceutical product containing either peptide exists in the United States market. Research-grade versions sold by peptide vendors are not approved drugs and have not gone through the approval process that would establish safety and efficacy for human use.
The FDA has approved other peptides that act on the GH axis for specific indications. Sermorelin, another GHRH analog, was approved as Geref for growth hormone deficiency in children, though it was later discontinued by its manufacturer for commercial reasons. Tesamorelin is approved as Egrifta for HIV-associated lipodystrophy. These approvals apply to those specific branded drugs under those specific indications, not to the broader class of GHRH analogs or secretagogues. CJC-1295 and Ipamorelin remain outside that approval framework entirely.
The FDA has also flagged growth hormone secretagogues as a category of concern in the context of compounding pharmacy regulations. Researchers and consumers looking at these compounds should be aware that the regulatory picture is not static, and the classification of peptides for compounding purposes has been an active area of agency attention.
What Distinguishes Them as Research Subjects?
The most meaningful distinction between CJC-1295 and Ipamorelin as research subjects is the quality and quantity of human data behind each. CJC-1295 with DAC has a published human pharmacokinetic profile. Researchers can point to a peer-reviewed study with 65 participants and specific measurements of GH and IGF-1 over time. That does not make it a proven therapeutic, but it does mean the basic pharmacokinetics in humans have been characterized in a published, reviewable format.
Ipamorelin's research story is more preclinical. The selectivity data from Raun et al. in 1999 is real and was an important finding in the GHS literature, but it was conducted in animals. The GI-motility clinical program showed that human trials were feasible, but that program addressed a completely different physiological system than the GH-axis effects most commonly associated with Ipamorelin in vendor marketing. The gap between what animal studies show and what human trials have confirmed is wide.
Vendors frequently market these two compounds together as a combination, implying synergy. The mechanistic rationale for synergy is scientifically grounded: GHRH-pathway and GHS-R1a-pathway co-stimulation does produce additive GH release in animal models. But human trial data on the combination specifically is not available in the published literature. Anyone evaluating vendor claims about the combination should weigh that absence carefully.
Vetted vendors for research use
Our index screens vendor documentation against the checks in this review. We never accept payment for rank placement.
Frequently asked questions
Is there a human clinical trial for CJC-1295?
Yes. A 2006 study published in the Journal of Clinical Endocrinology and Metabolism by Ionescu and Frohman enrolled 65 healthy adults and measured pharmacokinetic and pharmacodynamic responses to CJC-1295 with DAC. It found dose-dependent increases in GH and IGF-1 lasting up to six days. This was a pharmacokinetic and safety-signal study, not a long-term efficacy trial, and it did not establish CJC-1295 as a treatment for any condition.
Why do vendors almost always sell CJC-1295 and Ipamorelin together?
The pairing is based on the mechanistic argument that GHRH-receptor stimulation (CJC-1295) and GHS-R1a stimulation (Ipamorelin) are additive or synergistic at the pituitary level. Animal studies support the idea that combining a GHRH analog with a secretagogue produces greater GH release than either alone. However, published human trial data on this specific combination does not exist in the peer-reviewed literature, so the synergy claim in humans is extrapolated from preclinical work.
What was the Ipamorelin clinical trial for postoperative ileus, and what happened to it?
A Phase 2 trial registered as NCT00397956 on ClinicalTrials.gov tested an oral formulation of Ipamorelin for gastrointestinal motility recovery after bowel surgery. It was sponsored by Helsinn Therapeutics. The trial did not produce peer-reviewed published results supporting efficacy, and the program did not advance to Phase 3 or regulatory approval. This trial is notable because it represents the most substantial human research on Ipamorelin, but it addressed GI motility rather than the GH-axis effects most commonly discussed in peptide research communities.
Sources
Sources are listed most recent first. Cited studies are peer-reviewed unless noted.
- Ionescu and Frohman, 2006, Journal of Clinical Endocrinology and Metabolism Human pharmacokinetic trial of CJC-1295 with DAC
- Raun et al., 1998, European Journal of Endocrinology Ipamorelin selectivity profile in animal models
- ClinicalTrials.gov NCT00397956 Phase 2 Ipamorelin trial for postoperative ileus
Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds not approved by the FDA or any equivalent authority for human use outside prescribed contexts. Always consult a licensed clinician before any health decision.
